Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- EC Grants Marketing Authorization for Takeda’s ARB Edarbi
December 12, 2011
- Fuso Withdraws NDA for PHN Treatment in Japan, Prepares for Additional Studies
December 12, 2011
- Will Ilaris Remain an “Ultra-orphan” Drug?
December 10, 2011
- DODA Survey Shows MR’s Average Annual Income at ¥6.61 Million, 6th Highest by Occupation
December 9, 2011
- GSK’s Ofatumumab and Pazopanib Granted Orphan Drug Designation
December 9, 2011
- Kyowa Kirin Aims to Make RNAi Drugs Future Pillar: Dr Shitara
December 9, 2011
- Kobayashi, President of Mitsubishi Chemical HD Expects Continuous Growth of Pharmaceutical Business
December 9, 2011
- Takeda Says FDA Committee Indicates Recommendation for Peginesatide
December 9, 2011
- Shionogi Announces Favorable Decision in Fortamet Preliminary Injunction Proceedings
December 9, 2011
- MTPC Sets Up External Committee to Promote Appropriate Use of Telavic
December 8, 2011
- Mebiopharm, Nawaloka HD to Establish Joint Venture in Sri Lanka
December 8, 2011
- Towa Pharmaceutical to Expand Dealings with Regional Foundation Hospitals
December 7, 2011
- Growth for All Products Is Indispensable: President Alvarez of MSD
December 7, 2011
- FDA Accepts NDA for US BMS/US Pfizer’s Apixaban
December 7, 2011
- US Merck to Establish Asia R&D Headquarters in Beijing
December 7, 2011
- Sandoz Aiming for Top-10 Position in Japan within 3-5 Years
December 7, 2011
- Samsung, Biogen Idec Agree to Set Up Biosimilar Joint Venture Company
December 7, 2011
- Ethical Drug Sales Up 7% in October; 6th Monthly Increase in a Row: Crecon
December 7, 2011
- AnGes MG Reaches Agreement with Japanese, Korean Companies to Develop Therapeutic CIN Vaccine
December 6, 2011
- US Sunovion to Resubmit NDA for Antiepileptic Treatment STEDESA
December 6, 2011
ページ
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s FY2026 drug pricing reform is set to usher in a new phase for the generics market, effectively bringing an…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…